[{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm Expands Its Radiopharmaceutical Footprint with an Exclusive In-Licensing Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"Clovis Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology Submits IND for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$465.0 million","upfrontCash":"$40.0 million","newsHeadline":"3B Pharmaceuticals Enters Into a Global Exclusive Licensing Agreement for Its FAP-Targeting Peptide Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"GERMANY","productType":"Peptide","productStatus":"Undisclosed","date":"April 2023","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"RefleXion Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers Including Brain, Pancreatic and Liver","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by 3B Pharmaceuticals
Under the agreement, RefleXion to develop and commercialize a specific 3BP molecule, RXM-4768 which targets fibroblast activation protein (FAP) found in nearly all solid tumor types, to direct its SCINTIX™ biology-guided radiotherapy.
The agreement gives Novartis exclusive worldwide rights to develop and commercialize therapeutic and imaging applications for 3BP's FAP-targeting peptide technology, including FAP-2286.
Following clearance of the INDs by FDA, Clovis plans to initiate a Phase 1/2 clinical trial of lutetium-177 labeled FAP-2286 to determine the dose and tolerability of the FAP-targeting therapeutic agent, with expansion cohorts planned in multiple tumor types.
This agreement extends the radio-oncology portfolio of Debiopharm which currently includes another clinical stage radiotherapeutic and the radiotherapyenhancing antagonist of IAPs.